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Abstract
Around 45% of East Asians are unable to fully metabolize ethanol due to functional
polymorphisms of alcohol metabolism genes, specifically alcohol dehydrogenase (ADH)
and aldehyde dehydrogenase (ALDH). These individuals display high levels of toxic
blood acetaldehyde when consuming alcohol, causing symptoms such as tachycardia,
vomiting, and flushing. The studies included in this review examine how functional
polymorphisms of ADH and ALDH protect against alcoholism in addition to how
polymorphisms can be utilized as protection against alcoholism via gene therapy. The
studies included found that carriers of the ADH and ALDH polymorphisms were 66 to
99% genetically protected against alcoholism. Through the use of gene pharmacology
involving ADH and ALDH mimicry, gene therapy was seen to reduce ethanol intake in
several animal models, furthering the development of new treatments for alcoholism.
Keywords: aldehyde dehydrogenase, alcohol dehydrogenase, Asian, flush,
polymorphism, gene therapy, alcoholism
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Functional Polymorphisms of Alcohol Metabolism Genes and their Protection Against
Alcoholism via Gene Therapy: A Systematic Review
INTRODUCTION
Many individuals around the world consume alcohol in safe levels. However, a
significant number of individuals dangerously increase their alcohol intake in a way that
is susceptible to addiction and alcohol use disorder (AUD) (Enoch, 2014). AUD is a type
of substance use disorder (SUD) and is a moderately heritable chronic medical illness
that is very common, affecting an estimated 15 million people in the United States
(National Institute on Alcohol Abuse and Alcoholism, 2015). SUDs “are characterized by
clinically significant impairments in health, social function, and impaired control over
substance use and are precisely diagnosed through assessing cognitive, behavioral, and
psychological symptoms” (U.S. Department of Health and Human Services, 2016, pg. 6).
According to the Substance Abuse and Mental Health Services Administration (2017),
20.1 million people (6.2% of the US population) met the diagnostic criteria for SUD in
2016, but only 3.8 million individuals (18.9% of those with SUD) received any type of
treatment. In the case of SUD related to alcohol use, Hasin, Stinson, Ogburn, and Grant
(2007) noted that the lifetime prevalence of AUD in the United States is 30% and has
continued to rise each year.
When an individual becomes addicted to alcohol use, they experience the most
severe form of AUD. Addiction in the context of AUD is associated with compulsive and
uncontrolled use of alcohol (U. S. Department of Health and Human Services, 2016). The
process of developing an addiction to alcohol involves a number of functional genetic
factors in addition to environmental factors. According to Goldman, Oroszi, and Ducci
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(2005), the heritability of alcoholism is about 50%. However, only two genes have been
verified as “addiction genes” in the human body within the context of alcoholism:
mitochondrial aldehyde dehydrogenase (ALDH) and alcohol dehydrogenase (ADH)
(Goldman et al., 2005; Higuchi, Matsushita, Murayama, Takagi, & Hayashida, 1995;
Luczak, Glatt, & Wall, 2006). Both genes are polymorphic in humans, meaning that more
than one allele can occupy each gene’s locus along a chromosome within a population of
humans. For example, two forms of ALDH2 exist: ALDH2*2 and ALDH2*1. ALDH2*2
encodes the inactive form of the ALDH2 enzyme while ALDH2*1 encodes the active,
more frequent form of the ALDH2 enzyme. The difference in alleles located at each
gene’s locus results from changes in single nucleotides, which alter the activity of each
enzyme (Pautassi, Camarini, Quadros, Miczek, & Israel, 2010). This is known as a
single-nucleotide polymorphism (SNP) (C. Chen, Lu, Y. Chen, Wang, Chang, Li, & Yin,
1999). Because polymorphisms of each gene can alter the gene’s final functioning
capacity, all genetic variants of ALDH and ADH are both referred to as functional
polymorphisms.
The body’s way of metabolizing alcohol typically includes breaking down ethanol
within the liver via the ADH enzyme into acetaldehyde while then utilizing the ALDH
enzyme to further metabolize acetaldehyde into nontoxic acetate (Enoch, 2014; RiveraMeza, Quintanilla, Tampier, Mura, Sapag, & Israel, 2010). Those who have a
polymorphism in the ADH and ALDH enzymes are unable to properly metabolize
alcohol, leading to the accumulation of acetaldehyde, which is mutagenic and
carcinogenic to the body. Because the body is unable to fully metabolize ethanol, the
consumption of alcohol causes a buildup of acetaldehyde in the body which then causes
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symptoms of flushing, hypotension, nausea, headache, vomiting, and tachycardia,
ultimately discouraging further alcohol intake (Chen et al., 1999; Goldman et al., 2005;
Pautassi et al., 2010). This response to alcohol consumption is known as the flushing
response, Asian glow, and Asian flush (Higuchi et al., 1995). Individuals who possess
functional polymorphic alleles of ADH and ALDH are said to have a genetic protection
against alcohol abuse and alcoholism. In fact, individuals who are heterozygous
ALDH2*2/ALDH2*1 carriers are protected against alcohol abuse and alcoholism by 66
to 75% while homozygous ALDH2*2/ALDH2*2 carriers are nearly 100% protected
(Ocaranza, Quintanilla, Tampier, Karahanian, Sapag, & Israel, 2008). According to
Enoch (2014), approximately 45% of East Asians (Japanese, Chinese, Koreans, Thais)
are carriers of the ALDH2*2 allele. More specifically, approximately 31% of Chinese,
45% of Japanese, 29% of Koreans, and 10% of Thais carry at least one of the variant
ALDH2*2 allele (Luczak et al., 2006). However, the same allele is rare in Western and
Central European Whites; although it remains moderately prevalent in Russian and
Jewish Whites.
To understand the interaction between functional polymorphisms of the alcohol
metabolism genes and their protection against alcoholism, it is important to first
understand the variations and roles of the major enzymes of alcohol metabolism, ADH
and ALDH. Four genes are responsible for coding the four forms of ADH that are
involved in alcohol metabolism (Chen et al., 1999). The four forms of ADH can be split
between class I (ADH1-3) and class II (ADH4) enzymes. At the ADH2 locus, three
allelic variants are possible: ADH2*1, ADH2*2, and ADH2*3; at the ADH3 locus, two
allelic variants are possible: ADH3*1 and ADH3*2. These variations in alleles that code

4

for ADH can dramatically impact the enzyme’s rate of activity within the cell. The same
is true of the allelic variants of the two forms of ALDH: cytosolic ALDH1 and
mitochondrial ALDH2. The ALDH2 locus contains two allelic variations: ALDH2*1 and
ALDH2*2.
According to Chen et al. (1999), the alleles ADH2*2 and ADH3*1 code for
different forms of the high-activity ADH enzyme along with the ALDH2*2 allele that
codes for the low-activity form of ALDH2. The frequency of these three allelic variants
have been documented to be significantly low in alcoholics when compared to a general
population of East Asians. Chen and colleagues (1999) tested the hypothesis that the
allelic variants ADH2*2, ADH3*1, and ALDH2*2 provided substantial protection
against alcoholism through either faster production or slower removal of acetaldehyde
among 885 alcoholics and controls of Han Chinese descent in Taiwan. ADH2 and ADH3
haplotype frequencies were combined with ALDH2 genotypes and then compared
between the participants diagnosed with alcohol dependence (alcoholic group, n = 340;
315 males and 25 females; mean age = 40) and a control group (n = 545; mean age = 20)
comprised of male medical, dental, and pharmacy students that were either nondrinkers
or occasional light drinkers. Genomic DNA was extracted from subjects’ leukocytes and
then labeled via polymerase chain reactions (PCR) by their SNP sites to determine each
subject’s differences in genotypes and alleles associated with alcohol metabolism.
Chen et al. (1999) found that genotype and allele distributions of the alcohol
metabolism genes were not significantly different among the Han Chinese alcoholics
group; however, the genotype and allele distributions of the control group varied
significantly from the alcoholic group. When evaluating the separate roles of ADH2,
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ADH3, and ALDH2 in predisposition to alcoholism within three tested models
(codominance model, complete-dominance model, and partial-dominance model), they
found that the ADH3 locus failed to show a significant effect (p = .23-56) on risk for
alcoholism. Any previous reports of ADH3 having a significant protection against
alcoholism was attributed to linkage disequilibrium of the ADH2 and ADH3 alleles (p
< .013) based on the findings by Chen et al. (1999). The researchers, however, did find
that the ADH2*1/*2 and ADH2*2/*2 genotypes showed highly significant protection
against alcoholism (odds ratios [ORs], .12-.19) when compared to the ADH2*1/*1
genotype. When examining the combined effects of ADH2 and ALDH2, they found that
ADH2*2/*2-ALDH2*1/*2 carriers have a 20 - 25-fold less risk for alcoholism than
ADH2*1/*1-ALDH2*1/1 carriers. Most significantly, Chen et al. (1999) found that
ALDH2*2/*2 homozygosity appeared to completely protect against the development of
alcoholism while ALDH2*2/*1 heterozygosity displayed partial protection.
Chen and colleagues’ (1999) study was one of the first studies to incorporate such
a large number of subjects, assuring that their results could reflect valid population
statistics among Han Chinese in Taiwan. This study was also one of the first studies that
comprehensively tested the interactions between ADH2*2, ADH3*1, and ALDH2*2.
Similar results have been duplicated in several related studies since then, showing that
ALDH2*2/*2 homozygosity completely protects while ADH2*2/*2 homozygosity
partially protects (~50%) against the development of alcoholism (Chambers, Marshall,
Robinson, Maguire, Newton-Howes, & Chong, 2002; Garver, Tu, Cao, Aini, Zhou, &
Israel, 2001; Kim et al., 2008; Thomasson et al., 1991).
CURRENT SYSTEMATIC REVIEW
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While several studies have focused on the association between genetic influences
and their role in determining alcohol consumption patterns among individuals, relatively
few studies have considered the relationship between functional genetic polymorphisms
and their ability to be used as a therapy for alcoholism via gene therapy. This systematic
review paper focuses on studies that examine the functional polymorphisms of two liver
enzymes (ADH and ALDH) and their ability to be used as a genetic foundation for the
development of a potential, long-term treatment for alcoholism. In reviewing current
research concerning the characteristics of ADH and ALDH, this paper considers how
functional polymorphisms of the alcohol metabolism genes can be utilized as a protection
against alcoholism and how the use of gene therapy can further the current treatment
options for alcoholism.
METHOD
This systematic review was conducted using the procedures based on the
Cochrane Group guidelines for systematic reviews (van Tulder, Furlan, Bombardier,
Bouter, & the Editorial Board of the Cochrane Collaboration Back Review Group, 2003).
A flow diagram of the search is displayed in Figure 1. Search terms were developed and
integrated using Boolean logic to find studies targeting the specified population (e.g.,
adolescents, adults, humans, animals), intervention (e.g., gene therapy, adenovirus vector,
RNA, antisense gene), and outcome measurement (e.g., alcoholism, alcohol behaviors,
alcohol symptoms, alcohol use, ethanol intake). This systematic search was conducted
through electronic database searches to identify meeting all inclusion criteria as of March
2018. As displayed in Figure 1, five studies met inclusion criteria.
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Figure 1. Flow diagram of article search
RESULTS
Table 1 summarizes study methods and results for the five studies that met all
inclusion criteria. All studies included rats or rat cell lines; no studies included human
participants. Four studies incorporated versions of adenoviral vectors to alter rat genomes
while one study utilized antisense oligonucleotides to alter rat genomes. Of the
8

adenoviral vector studies, two examined the impact adenoviral vectors would have on
ALDH activity on rats in vivo and in vitro, one examined the impact adenoviral vectors
would have on ADH activity in vivo, and one examined the impact adenoviral vectors
would have on both ADH and ALDH in vivo. The adenoviral vector studies included the
use of Aldh2 antisense vectors (AdV-AS) (n = 2), both AdV-rADH-47His and AdVrADH-47Arg vectors (n = 1), and AdV-ADH/asALDH2 vectors (n = 1) to test respective
activity levels of ALDH2, ADH, and ADH/ALDH2 after the consumption of ethanol.
The oligonucleotide study included in this systematic review examined the impact
antisense phosphorothioate oligonucleotide (ASO) would have on ALDH activity in vivo.
All five studies found that respective enzyme activity was reduced after the
introduction of either adenoviral vectors or oligonucleotides (Garver et al., 2001;
Karahanian, Ocaranza, & Israel, 2005; Ocaranza et al., 2008; Rivera-Meza et al., 2010;
Rivera-Meza, Quintanilla, & Tampier, 2012). Furthermore, all five studies showed
increased acetaldehyde levels within infected cells after undergoing gene therapy. This
reveals that gene therapy within the context of alcohol metabolism is able to mimic the
reactions of polymorphic human cells within rat models.
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Table 1. Study Methods and Results
Article

Garver, Tu,
Cao, Aini,
Zhou, &
Israel
(2001)

Conditions

Type

Antisense
Phosphorothioate
oligonucleotide
(ASO)

ASO-9
(intravenous
administration)

ASO-9
(intraperitoneal
administration)

Karahanian,
Ocaranza,
& Israel
(2005)

Ocaranza,
Quintanilla,
Tampier,

Control

Control
oligonucleotide

Adenoviral vector
(MOI: 5)

Aldh2 antisense
(AdV-AS)
vector

Adenoviral vector
(MOI: 15)

Aldh2 antisense
(AdV-AS)
vector

Control

AdV-noncoding
(AdV) vector

Adenoviral
vector
vp
(1 𝑥 1012 kg )

Anti-Aldh2
(AdV-AS)
vector

Ethanol
Dose
1 g/kg
ethanol

N

Male Lewis
rats

Age or
Weight
Weight:
200-300 g

6%
vol/vol
ethanol

10mM
ethanol

10%
ethanol

30 100 mm
dishes of rat
hepatoma
cells

4 female
rats/condition

N/A

2 months

Ethanol Exposure
Procedures

Measurement

Findings
•

Rats treated for 4
days at 15 mg
ASO-9/kg/day;
oral ethanol
administered on
day 5 (1 g/kg);
killed after 60
min
Rats treated for 3
days at 24
mg/kg/day;
ethanol
administered on
day 4

ALDH activity,
mRNA expression,
and acetaldehyde
levels determined

Rat hepatoma cells
infected with
vectors; cells
incubated with
ethanol for 1 h

ALDH2 activity and
Acetaldehyde
levels determined
using a series of
chemical reactions

•

60 d voluntary
access to 10%
ethanol; ethanol

Voluntary water and
ethanol intake
recorded; ALDH

•

•

•

•

ASO-9 led to 38-45%
reduction in ALDH2 activity
and four-fold increase in
acetaldehyde levels compared
to control oligonucleotide
After 1 h of ethanol
consumption, ASO-9 groups
displayed 61% reduction in
ethanol consumption (p <
0.015) compared to control
After 5 h of ethanol
consumption, ASO-9 groups
displayed 45% reduction in
ethanol consumption (p <
0.035) compared to control

48 h after transduction of
Aldh2 antisense gene led to
reduction in ALDH2 activity
(60-70%; p < 0.001)
Aldh2 antisense gene led to
eight-fold increase in
acetaldehyde levels (p < 0.001)

AdV-AS treated animals
consumed 50% less ethanol
during 34 day study compared
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Karahanian,
Sapag, &
Israel
(2008)

Control
AdV-C vector

Rivera-Meza,
Quintanilla,
Tampier,
Mura,
Sapag, &
Israel
(2010)

Adenoviral vector
vp
(5 𝑥 1012 kg)

Adenoviral vector
vp
(5 𝑥 1012 kg)

AdV-rADH47His vector
(mutant)

10%
ethanol

5 female
rats/condition

16 weeks
Weight:
150-200 g

withdrawn, AdV
administered;
Limited access
paradigm: access to
ethanol and water
for 1 h each day for
34 days 72 h after
adenoviral vector
injection

activity and mRNA
expression
determined

Limited access
paradigm: Access
to ethanol and
water for 1 h each
day for 13 days

Voluntary water and
ethanol intake
recorded; arterial
acetaldehyde levels
determined on day
21 using gas
chromatography

AdV-rADH47Arg vector
(wildtype)

•

•

•

•

Rivera-Meza,
Quintanilla,
& Tampier
(2012)

Control

AdV-noncoding
vector

Multiple expression
cassette
adenoviral vector
vp
(3 𝑥 1012 kg)

AdVADH/asALDH2

Control

AdV-C

10%
ethanol

6 female
rats/condition

16 weeks
Weight:
150-200 g

Limited access
paradigm: Access to
ethanol and water
for 1 h each day for
15 days before
adenoviral vector
injection; Access to
ethanol and water
for 1 h each day for
23 days 72 h after
adenoviral vector
injection

Voluntary water and
ethanol intake
recorded; arterial
acetaldehyde levels
determined using gas
chromatography;
ADH and ALDH2
levels determined

•

•

•

•

to AdV-C treated animals (p <
0.001)
Liver ALDH activity of AdVAS treated animals was 85%
reduced compared to AdV-C
treated animals (p < 0.002)

AdV-rADH-47His vector
showed lower voluntary
ethanol intake (50% reduction;
p < 0.001) than animal with
AdV-noncoding vector
AdV-rADH-47Arg vector
showed lower voluntary
ethanol intake (30% reduction;
p < 0.01) than animals with
AdV-noncoding vector
ADH activity in animals with
AdV-rADH-47His vector (90%;
p < 0.01) and AdV-rADH47Arg vector (32%; p < 0.01)
were higher than animals with
AdV-noncoding vector
AdV-ADH/asALDH2 vector
showed reduced voluntary
ethanol intake for 3 weeks
(60%; p < 0.001) compared to
AdV-C vector animals
AdV-ADH/asALDH2 vector
showed increased levels of
blood acetaldehyde with peak
at 5-10 min after ethanol
administration (400%; p
<0.001) compared to AdV-C
vector animals
AdV-ADH/asALDH2 vector
showed increased activity of
ADH (176%; p <0.001)
compared to AdV-C vector
animals
AdV-ADH/asALDH2 vector
showed decreased activity of
liver ALDH2 (24%; p <0.01)
compared to AdV-C vector
animals
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To determine ALDH2 activity in the Karahanian et al. (2005) study, total RNA was
extracted from hepatoma cells. Antisense RNA was separated from endogenous RNA via reverse
transcriptase (RT) reactions followed by PCR. ALDH2 activity was then measured. According to
Karahanian et al. (2005), high levels of both antisense mRNA and sense mRNA was found in
cells infected with the adenoviral vector carrying the antisense gene; however, antisense mRNA
did not increase at higher multiplicities of infection (MOIs) of the viral vector. Furthermore,
ALDH2 activity was reduced 60-70% (p < 0.001) forty-eight hours after transduction of the
Aldh2 antisense gene while acetaldehyde levels in cells infected with the antisense coding gene
increased eight-fold (p < 0.001). Although ALDH2 activity showed slight differences at varying
MOIs, acetaldehyde levels remained the same between the two MOI conditions. Karahanian and
colleagues (2005) hypothesized that ALDH may begin removing acetaldehyde at high levels due
to its higher 𝐾𝑚 value, preventing further accumulation of acetaldehyde at a higher MOI.
Overall, Karahanian et al. (2005) showed the administration of an adenoviral vector carrying an
Aldh2 antisense gene is able to increase the levels of acetaldehyde in rat cells metabolizing
ethanol, successfully mimicking the effects of the functional polymorphism ALDH2*2 in
humans metabolizing ethanol.
In a following study, Ocaranza and colleagues (2008) used rats bred as high alcohol
drinkers as their subjects. Over the course of 2 months during which the rats were offered
voluntary consumption of ethanol (10%) and water, all rats became alcohol dependent.
Following this 2-month period, one group of rats (n = 4) had the therapeutic AdV administered
via the tail vein while another group (n = 4) had a control AdV administered. All rats were then
subjected to a 3-day withdrawal period during which they had no access to ethanol. After the
withdrawal period, the two groups of rats were allowed access to a 10% ethanol solution (for

only one hour a day) and water (all day) for the following 34 days. Consumption patterns were
recorded for all rats. Thirty-five days after the withdrawal period, the rats were euthanized and
their liver ALDH2 activity was determined.
Ocaranza et al. (2008) observed that both groups of rats consumed intoxicating amounts
of alcohol on the first day of ethanol re-access after the withdrawal period. However, over the
next 34 days, the rats who had been administered the therapeutic AdV (AdV-AS) showed a
dramatic reduction (50% lower than control AdV; p = 0.001) in ethanol intake while the rats
who had been administered the control AdV (AdV-C) continued to consume ethanol at a high
rate. The reduction in ethanol consumption was evident five days after the AdV-AS was injected
and stabilized after 12 - 13 days. When analyzing liver ALDH2 activity, the researchers found
that liver activity was reduced by 85% in rats that had received AdV-AS in comparison to the
liver activity of those that had received AdV-C. Most importantly, this study found that gene
therapy that mimics the low ALDH2 phenotype can elicit deterrence to high alcohol drinking
even after high alcohol drinking has been established. The study done by Ocaranza and
colleagues (2008) successfully showed that the single administration of the AdV carrying an
anti-ALDH2 antisense gene was not only able to reduce liver ALDH2 activity, but it was also
able to reduce alcohol intake for 34 days, which was the longest period of time studied up until
that point. This study shows that gene therapy can be used as a possible long-term treatment
option for alcohol-dependent animals and may be further developed into a long-term treatment
option for humans with alcoholism.
To further investigate the mechanism by which alcohol metabolism polymorphisms
protect against heavy alcohol intake, Rivera-Meza et al. (2010 & 2012) studied alcohol intake in
rats transduced with the rat analog of the human ADH2*2 gene as well as with the rat analog of
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the human ALDH2*2 gene in combination with the ADH2*2 gene. In the 2010 study, RiveraMeza and colleagues cloned rat wild-type ADH (47Arg) and mutant ADH (47His) using
methods similar to Karahanian et al. (2005) and Ocaranza et al. (2008) with the exception of
using different promoter sequences and plasmids. Following this, adenoviral vectors AdVrADH-47His and AdV-rADH-47Arg were formed, purified, and intravenously injected into each
rat depending on which condition they were assigned (n = 6/condition). The rats were then
allowed access to a 10% ethanol solution and water for 1 hour each day for 13 days before being
euthanized to determine arterial acetaldehyde levels. According to Rivera-Meza et al. (2010),
liver ADH activity within animals transfected with AdV-rADH-47His was six times higher than
that within animals transfected with AdV-rADH-47Arg and 90% higher than that within animals
transfected with the control AdV (p < 0.01). Additionally, animals that received the AdV-rADH47His vector showed a significantly lower voluntary ethanol consumption level (50% reduction;
p <0.001) than animals that received the control AdV. Overall, ADH2*2 showed that high levels
of blood acetaldehyde occur only during the first few minutes of ethanol metabolism, resulting in
a “burst” of acetaldehyde, which causes the reduction in voluntary ethanol intake. This “burst” is
primarily caused by AdV-rADH-47His having a higher 𝐾𝑚 for NAD+ at its active site and a 6fold higher 𝑉𝑚𝑎𝑥 than AdV-rADH-47Arg.
In order to expand upon their previous research, Rivera-Meza et al. (2012) developed a
new therapeutic strategy to treat alcoholism by increasing ADH activity while also reducing
ALDH2 activity to produce higher blood levels of acetaldehyde during ethanol metabolism. By
doing so, the expression of both protective genes could be provided within a single adenoviral
vector. In this study, Rivera-Meza and colleagues (2012) developed a multiple expression
cassette adenoviral vector (AdV-ADH/asALDH2) that encoded both a fast rat ADH and an
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antisense RNA against rat ALDH2. The adenoviral vector was formed using similar methods to
that of which was previously described in the 2010 study. The rats in this study were allowed
access to a 10% ethanol solution and water for 1 hour each day for 15 days before being
intravenously injected with AdV-ADH/asALDH2. Seventy-two hours after the injection, rats
were allowed access to ethanol and water for 1 hour each day for 23 days as researchers
observed their ethanol intake. After the trial period, rats were subjected to seven days of
abstinence from ethanol intake. After the abstinence period, the rats were given another dose of
ethanol (1 g/kg) before being euthanized to measure acetaldehyde levels throughout the body.
Rivera-Meza et al. (2012) found that AdV-ADH/asALDH2 infected animals showed
increased activity of ADH (176%; p <0.001) and decreased activity of liver ALDH2 (24%; p
<0.01) compared to AdV-C vector animals. Likewise, AdV-ADH/asALDH2 vector showed
reduced voluntary ethanol intake for 3 weeks (60%; p < 0.001) compared to AdV-C vector
animals due to increased levels of blood acetaldehyde that peaked at 5-10 min after ethanol
administration (400% increased; p <0.001). Overall, this study showed that the paired increase of
ADH activity and reduction of ALDH2 activity in the liver of alcohol-dependent rats is an
effective method to reduce the voluntary ethanol intake in rodents, providing evidence of new
therapeutic strategies for the treatment of alcoholism.
In a study by Garver et al. (2001), manufactured antisense phosphorothioate
oligonucleotides (ASO), specifically ASO-9, was purchased and intravenously administered via
a femoral venous catheter (15 mg ASO-9/kg/day) in rats for four days. On day five, an oral
ethanol was administered (1 g/kg) and then the rats were euthanized one hour later in order to
determine acetaldehyde levels and ALDH activity. Rats receiving the ASO-9 treatment showed a
50% reduction in ALDH2 mRNA compared to those receiving the control treatment. ALDH2
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activity was reduced by 38-45% and displayed a four-fold increase in acetaldehyde levels after
ethanol administration under ASO-9 treatment conditions in comparison to the rats in the control
treatment.
To determine if ASO-9 could result in an aversion to ethanol and reduced ethanol
consumption, Garver et al. (2001) surgically implanted rats with osmotic pumps which delivered
ASO-9 at 24 mg/kg/day intraperitoneally. Three days after implantation with no access to water
on the last night, rats were offered 6% ethanol as the only fluid and consumption was observed
and measured at five hour intervals. During the first hour of ethanol presentation, initial ethanol
consumption was similar in both the ASO-9 and control groups, resulting in 1.12 ± 0.9 g
ethanol/kg (ASO-9) and 1.70 ± 0.68 g ethanol/kg (control). After the first hour, consumption was
reduced significantly (p < 0.015) in the ASO-9 group (0.48 ± 0.23 g ethanol/kg) compared with
the control group (1.22 ± 0.116 g ethanol/kg). Overall, a 45% reduction in ethanol consumption
in ASO-9 treated animals was measured in comparison to animals receiving the control treatment
(p <0.035).
All five studies included in this systematic review were able to utilize gene therapy
techniques to mimic the functional polymorphisms of alcohol metabolism genes found primarily
in East Asians within rat studies. As a result, all of the studies were able to lower their respective
enzyme activities and elevate acetaldehyde levels after the administration of ethanol. In the in
vivo studies, the elevated acetaldehyde levels resulted in an aversion to ethanol intake as shown
by a reduction in alcohol consumption.
DISCUSSION
Several studies found that individuals who possess functional polymorphic alleles of the
ADH and ALDH2 genes are genetically protected against alcohol abuse and alcoholism (Chen et

16

al., 1999; Higuchi et al., 1995; Ocaranza et al., 2008). In fact, individuals who are heterozygous
ALDH2*2/ALDH2*1 carriers were protected against alcohol abuse and alcoholism by around 66
to 75% while homozygous ALDH2*2/ALDH2*2 carriers were nearly 100% protected (Chen et
al., 1999; Ocaranza et al., 2008). ALDH2*2/*1 heterozygosity was found to display partial
protection against alcoholism due to the presence of ALDH2*2 while individuals who were
ALDH2*2/*1 heterozygous inactive and ADH2*1/*1 homozygous active still had a significantly
high risk of alcoholism (Chen et al., 1999; Higuchi et al., 1995). However, individuals who were
ALDH2*2/*1 heterozygous inactive and ADH2*2/*2 homozygous inactive were largely
protected against risk of alcoholism.
In the study done by Ocaranza and colleagues (2008), liver ALDH2 activity was reduced
via a single administration of the AdV carrying an anti-ALDH2 antisense gene; the therapeutic
AdV was also able to reduce alcohol intake for 34 days in rats, which was the longest period
studied up until that point. This study along with the studies done Karahanian et al. (2005) and
Garver et al. (2001) reveal that gene therapy that mimics the polymorphic nature of ALDH can
be used as a possible long-term treatment option for alcohol-dependent animals. Furthermore,
these studies showed that deterrence can be elicited after high alcohol drinking has been
established, elevating the ability of gene therapy to be used as a possible treatment option for
humans with alcoholism. According to Karahanian et al. (2005), therapeutic reduction of
ALDH2 activity in the liver should be the primary aim in order to allow other tissues within the
lungs, upper respiratory tract, and upper gastrointestinal tract to retain their ability to metabolize
acetaldehyde. In doing so, risk of alcoholism in addition to risk of developing
oropharyngolaryngeal, esophageal, and lung cancer due to the carcinogenic effects of
acetaldehyde can be lowered.
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The two studies done by Rivera-Meza et al. (2010 & 2012) incorporated gene therapy
focused on ADH involvement in alcohol metabolism. In doing so, they found that ADH
polymorphisms play a large contributing factor in ethanol aversion due to a burst in acetaldehyde
production. Additionally, Rivera-Meza et al. (2012) found that simultaneously increasing ADH
activity and reducing ALDH2 activity was able to reduce the voluntary ethanol intake in rodents,
which provides evidence of new therapeutic strategies for the treatment of alcoholism.
In order to bridge the gap between gene therapy used in animal studies and any potential
future studies involving human subjects, more studies that consider the relationship between
functional genetic polymorphisms and their interactions with developmental stages and
variations in environmental context need to be pursued so that our understanding of how
polymorphisms such as ADH and ALDH work to protect humans against alcoholism throughout
their lifespan can be improved. Likewise, a greater number of animal studies that include larger
sample populations need to be tested before implementing similar gene therapy techniques in
humans to decrease the risk of alcoholism to ensure that methods are safe and that results are
able to be reproduced and to the same magnitude.
Future animal studies should test the effect of gene therapies similar to the ones described
within the studies included in this systematic review with the addition of longer periods of
abstinence during the withdrawal phase to more closely mimic the behavior of recovering
alcoholics. To test this, helper-dependent AdVs (HD-AdV) that are able to express therapeutic
genes for up to two years without the use of endogenous viral genes can potentially be used in
future rat and nonhuman primate studies (Rivera-Meza et al., 2012). The large cloning capacity
and ability to accommodate multiple transgenes and lower chronic toxicity of helper-dependent
adenoviruses allow them to be a plausible candidate vector for future liver-directed gene therapy.
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Furthermore, due to the intrinsic hepatotoxic effects of ethanol and the prolonged exposure to
ethanol within the gene therapy studies discussed in this systematic review, future studies should
be aware of and examine increases of acute and chronic hepatotoxicity of adenoviral vector
administration in animals.
Future studies involving human subjects should focus on the gene-environment
interaction of ADH/ALDH and sociocultural factors/developmental stages. Likewise, important
sociocultural variables such as mental health, personality traits, and relationships with parents
need to be considered. These variables require that future studies utilize a longitudinal design so
that fluctuations in the aforementioned variables are able to be observed and assessed effectively.
Future studies should also strive to include other ethnicities (Middle East Asians, Caucasians,
African Americans, etc.) when examining the gene-environment interaction seeing that familial,
cultural, and peer interactions play a significant role in determining the protective effects of
genes on alcoholism. These problems may be addressed within longitudinal studies that focus on
alcohol behaviors and thought processes within a variety of ethnically different communities. As
suggested by Irons, Iacono, Oetting, and Mcgue (2012), future studies should also examine
measures such as levels of access to alcohol with the house, family/peer alcohol use, and overall
beliefs on alcohol. Examining the gene-environment interaction is critical to any future
understanding of how to better our currently existing treatments for alcoholism in both young
adolescents and adults, and it is a necessary component to consider when bridging the gap
between animal studies and future gene therapy techniques developed for humans.
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